ALX Oncology approved an inducement stock option grant of 800,000 shares to Jeff Knight, the newly appointed Chief Development and Operating Officer, as part of his employment commencement. The options have an exercise price of $1.68 per share, matching the closing stock price on the grant date, and vest over four years with a one-year cliff. This move aims to attract and retain experienced leadership to advance ALX Oncology's clinical-stage cancer therapies, including its lead candidate evorpacept and pipeline drug ALX2004. The inducement grant complies with Nasdaq Listing Rule 5635(c)(4).
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
